Search

Displaying results 5531 - 5540 of 10000 in total
  1. Drug

    Elzovantinib

    go.drugbank.com/drugs/DB18918
    Investigational

    Elzovantinib is under investigation in clinical trial NCT03993873 (Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET).

  2. Drug

    Sofituzumab vedotin

    go.drugbank.com/drugs/DB15349
    Investigational

    Sofituzumab vedotin is under investigation in clinical trial NCT01335958 (Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable

  3. Drug

    Izalontamab brengitecan

    go.drugbank.com/drugs/DB22567
    Investigational

    Izalontamab brengitecan is under investigation in clinical trial NCT07054567 (A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial

  4. Drug

    DCLL-9718S

    go.drugbank.com/drugs/DB17392
    Investigational

    DCLL9718S is under investigation in clinical trial NCT03298516 (A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine

    Synonyms: THIOMAB antibody drug conjugate comprised of humanized IgG1 anti-C-type lectin-like molecule-1 monoclonal antibody and DNA alkylating cross-linking agent pyrrolo [2,1-c][1,4] benzodiazepine dimer
  5. Drug

    Acepromazine

    go.drugbank.com/drugs/DB01614
    InvestigationalVet approved

    Acepromazine is one of the phenothiazine derivative psychotropic drugs, used little in humans, however frequently in animals as a sedative and antiemetic.

  6. Drug

    Benfluorex

    go.drugbank.com/drugs/DB09022
    ApprovedWithdrawn

    The European Medicines Agency (EMA) recommended withdrawing all benfluorex containing medicines on 18 December 2009. … This recommendation was based on the risks (especially fenfluramine-like cardiovascular side-effects) outweighing the benefits.

  7. Drug

    VP025

    go.drugbank.com/drugs/DB05133
    Experimental

    VP025, a novel drug formulation based on phospholipid microparticles incorporating phosphatidylglycerol, can inhibit neuroinflammation. … It also shows the ability to reduce inflammation across the blood-brain barrier and improve correlates of memory and learning function.

  8. Drug

    IN01

    go.drugbank.com/drugs/DB16434
    Experimental

    The study will explore the effect of this vaccine on pulmonary function, oxygen saturation, quality of life, and fibrosing status in addition to biomarkers and molecular markers of the vaccine. … Administration of the vaccine stimulates the production of anti-epidermal growth factor (anti-EGF) neutralizing antibodies[L30543].

  9. Drug

    Pilaralisib

    go.drugbank.com/drugs/DB11772
    Investigational

    Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). … Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, among others.

  10. Drug

    DG051

    go.drugbank.com/drugs/DB05177
    Experimental

    DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation. … DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack.